An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine

Migraine, With or Without Aura Clinical Trial

Official title:
A Multicenter, Randomized, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura

Status Completed

Clinical Trial Summary

This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.

Clinical Trial Description

Usual care is the open-label control arm. Dose of ubrogepant (50 mg or 100 mg) will be double-blind for active treatment arms. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02873221
Study type	Interventional
Source	Allergan
Contact
Status	Completed
Phase	Phase 3
Start date	September 13, 2016
Completion date	August 2, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02848326` - Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention	Phase 2/Phase 3
Completed	`NCT03237845` - Safety and Efficacy in Adult Subjects With Acute Migraines	Phase 3
Completed	`NCT02828020` - Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine	Phase 3
Completed	`NCT03235479` - Safety and Efficacy Study in Adult Subjects With Acute Migraines	Phase 3
Completed	`NCT03461757` - Trial in Adult Subjects With Acute Migraines	Phase 3
Completed	`NCT03266588` - Open Label Safety Study in Acute Treatment of Migraine	Phase 2/Phase 3
Completed	`NCT02867709` - Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine	Phase 3